These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25516542)

  • 1. Vif determines the requirement for CBF-β in APOBEC3 degradation.
    Yoshikawa R; Takeuchi JS; Yamada E; Nakano Y; Ren F; Tanaka H; Münk C; Harris RS; Miyazawa T; Koyanagi Y; Sato K
    J Gen Virol; 2015 Apr; 96(Pt 4):887-892. PubMed ID: 25516542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small ruminant lentiviral Vif proteins commonly utilize cyclophilin A, an evolutionarily and structurally conserved protein, to degrade ovine and caprine APOBEC3 proteins.
    Yoshikawa R; Izumi T; Nakano Y; Yamada E; Moriwaki M; Misawa N; Ren F; Kobayashi T; Koyanagi Y; Sato K
    Microbiol Immunol; 2016 Jun; 60(6):427-36. PubMed ID: 27193350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Core-binding factor subunit beta is not required for non-primate lentiviral Vif-mediated APOBEC3 degradation.
    Ai Y; Zhu D; Wang C; Su C; Ma J; Ma J; Wang X
    J Virol; 2014 Oct; 88(20):12112-22. PubMed ID: 25122780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction.
    Zhang W; Du J; Evans SL; Yu Y; Yu XF
    Nature; 2011 Dec; 481(7381):376-9. PubMed ID: 22190036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Naturally Occurring Domestic Cat APOBEC3 Variant Confers Resistance to Feline Immunodeficiency Virus Infection.
    Yoshikawa R; Izumi T; Yamada E; Nakano Y; Misawa N; Ren F; Carpenter MA; Ikeda T; Münk C; Harris RS; Miyazawa T; Koyanagi Y; Sato K
    J Virol; 2016 Jan; 90(1):474-85. PubMed ID: 26491161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A conflict of interest: the evolutionary arms race between mammalian APOBEC3 and lentiviral Vif.
    Nakano Y; Aso H; Soper A; Yamada E; Moriwaki M; Juarez-Fernandez G; Koyanagi Y; Sato K
    Retrovirology; 2017 May; 14(1):31. PubMed ID: 28482907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple lysines combined in HIV-1 Vif determines the responsiveness to CBF-β.
    Ai Y; Ma J
    Biochem Biophys Res Commun; 2015 Feb; 457(3):385-90. PubMed ID: 25582776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of HIV-1 Vif regions required for CBF-β interaction and APOBEC3 suppression.
    Wang H; Liu B; Liu X; Li Z; Yu XF; Zhang W
    PLoS One; 2014; 9(5):e95738. PubMed ID: 24810617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection.
    Jäger S; Kim DY; Hultquist JF; Shindo K; LaRue RS; Kwon E; Li M; Anderson BD; Yen L; Stanley D; Mahon C; Kane J; Franks-Skiba K; Cimermancic P; Burlingame A; Sali A; Craik CS; Harris RS; Gross JD; Krogan NJ
    Nature; 2011 Dec; 481(7381):371-5. PubMed ID: 22190037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolutionarily conserved requirement for core binding factor beta in the assembly of the human immunodeficiency virus/simian immunodeficiency virus Vif-cullin 5-RING E3 ubiquitin ligase.
    Han X; Liang W; Hua D; Zhou X; Du J; Evans SL; Gao Q; Wang H; Viqueira R; Wei W; Zhang W; Yu XF
    J Virol; 2014 Mar; 88(6):3320-8. PubMed ID: 24390335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism.
    Marin M; Golem S; Rose KM; Kozak SL; Kabat D
    J Virol; 2008 Jan; 82(2):987-98. PubMed ID: 17977970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction.
    Duan S; Wang S; Song Y; Gao N; Meng L; Gai Y; Zhang Y; Wang S; Wang C; Yu B; Wu J; Yu X
    J Biol Chem; 2020 Oct; 295(43):14592-14605. PubMed ID: 32817167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dispersed and conserved hydrophobic residues of HIV-1 Vif are essential for CBFβ recruitment and A3G suppression.
    Zhou X; Han X; Zhao K; Du J; Evans SL; Wang H; Li P; Zheng W; Rui Y; Kang J; Yu XF
    J Virol; 2014 Mar; 88(5):2555-63. PubMed ID: 24352440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feline Immunodeficiency Virus Evolutionarily Acquires Two Proteins, Vif and Protease, Capable of Antagonizing Feline APOBEC3.
    Yoshikawa R; Takeuchi JS; Yamada E; Nakano Y; Misawa N; Kimura Y; Ren F; Miyazawa T; Koyanagi Y; Sato K
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Core Binding Factor β Protects HIV, Type 1 Accessory Protein Viral Infectivity Factor from MDM2-mediated Degradation.
    Matsui Y; Shindo K; Nagata K; Yoshinaga N; Shirakawa K; Kobayashi M; Takaori-Kondo A
    J Biol Chem; 2016 Nov; 291(48):24892-24899. PubMed ID: 27758855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Species-specific differences in the ability of feline lentiviral Vif to degrade feline APOBEC3 proteins.
    Yoshikawa R; Nakano Y; Yamada E; Izumi T; Misawa N; Koyanagi Y; Sato K
    Microbiol Immunol; 2016 Apr; 60(4):272-9. PubMed ID: 26935128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular requirements for bovine immunodeficiency virus Vif-mediated inactivation of bovine APOBEC3 proteins.
    Zhang W; Wang H; Li Z; Liu X; Liu G; Harris RS; Yu XF
    J Virol; 2014 Nov; 88(21):12528-40. PubMed ID: 25142583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.
    Zhang Z; Gu Q; Jaguva Vasudevan AA; Jeyaraj M; Schmidt S; Zielonka J; Perković M; Heckel JO; Cichutek K; Häussinger D; Smits SHJ; Münk C
    J Virol; 2016 Nov; 90(22):10193-10208. PubMed ID: 27581978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dominant Negative Mutants of Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) Disrupt Core-Binding Factor Beta-Vif Interaction.
    Duan S; Yu X; Wang C; Meng L; Gai Y; Zhou Y; Gu T; Yu B; Wu J; Yu X
    J Virol; 2022 Sep; 96(17):e0055522. PubMed ID: 35950859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.